Kyung-Ran Park

Rutaecarpine suppresses osteosarcoma progression and tumor-induced bone destruction by targeting the PRAS40-associated signaling network in an ex vivo metastasis model.

Despite advances in current therapeutic strategies, osteosarcoma remains a highly aggressive malignancy with limited treatment options. Rutaecarpine (Rut), an indolopyridoquinazolinone alkaloid with selective cyclooxygenase-2 inhibitory activity, has been reported to possess diverse pharmacological properties; however,...